Current Osteoporosis Reports

, Volume 9, Issue 1, pp 31–35

Osteoporosis in Men: What has Changed?

Article

Abstract

Osteoporosis in men is finally receiving some attention; it has been realized that men are more likely to die after hip fracture. Methods for screening men for osteoporosis include dual energy x-ray absorptiometry and use of fracture risk calculators such as FRAX (World Health Organization) and the Garvan nomogram. Evaluation of men will often identify secondary causes of osteoporosis as well as multiple risk factors. Alendronate, risedronate, zoledronic acid, and teriparatide are US Food and Drug Administration (FDA)—approved therapy for men. Men on androgen deprivation therapy (ADT) are at high risk for bone loss and fracture, and all the bisphosphonates have been shown to increase bone density. The new antiresorptive drug, denosumab, although FDA-approved only for postmenopausal women, has been shown in a study of men on ADT to increase bone density in spine, hip, and forearm and decrease vertebral fractures on x-ray. Thus, there is great progress in osteoporosis in men, and recognition of its importance is increasing.

Keywords

Osteoporosis Men Fracture Screening Dual-energy x-ray absorptiometry Testosterone Androgen deprivation therapy Bisphosphonates Teriparatide Denosumab 

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Schuit SCE, van der Klift M, Weel AEAM, et al. Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam study. Bone 2004, 34:195–202.CrossRefPubMedGoogle Scholar
  2. 2.
    Bass E, French DD, Bradham DD, Rubenstein LZ. Risk adjusted mortality rates of elderly veterans with hip fractures. Ann Epidemiol 2007, 17:514–519.CrossRefPubMedGoogle Scholar
  3. 3.
    Riggs BL, Melton LJ 3rd. Involutional osteoporosis. N Engl J Med 1986, 314:1676–1686.CrossRefPubMedGoogle Scholar
  4. 4.
    Adler RA: Osteoporosis in men. In Osteoporosis—Pathophysiology and Clinical Management 2nd Edition. Edited by Adler RA, New York, Humana/Springer; 2010:545–557.Google Scholar
  5. 5.
    • Khosla S, Amin S, Orwoll E. Osteoporosis in men. Endocrine Reviews 2008, 29:441–464. This is a comprehensive overview of the subject. CrossRefPubMedGoogle Scholar
  6. 6.
    • Ryan CS, Petkov VI, Adler RA. Osteoporosis in men: the value of laboratory testing. Osteoporos Int 2010, published on line October 9. This recent publication provides information on how to evaluate men with osteoporosis. Google Scholar
  7. 7.
    • Papaioannu A, Kennedy CC, Cranney A, et al. Risk factors for low BMD in healthy men age 50 years or older: a systematic review. Osteoporos Int 2009, 20:507–518. This is a systematic review of osteoporosis risks in men. CrossRefGoogle Scholar
  8. 8.
    Trimpou P, Landin-Wilhelmsen K, Oden A, Rosengren A, Wilhelmsen L. Male risk factors for hip fracture—a 30-year follow-up study in 7,495 men. Osteoporos Int 2010, 21:409–416.CrossRefPubMedGoogle Scholar
  9. 9.
    Cummings SR, Cawthon PM, Ensrud KE, et al. BMD and risk of hip and nonvertebral fracture in older men: a prospective study and comparison with older women. J Bone Miner Res 2006, 21:1550–1556.CrossRefPubMedGoogle Scholar
  10. 10.
    Fink HA, Ewing SK, Ensrud KE, et al. Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. J Clin Endocrinol Metab 2006, 91:3908–3915.CrossRefPubMedGoogle Scholar
  11. 11.
    Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore longitudinal study of aging. J Clin Endocrinol Metab 2001, 86:724–731.CrossRefPubMedGoogle Scholar
  12. 12.
    Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010, published on line June 16.Google Scholar
  13. 13.
    Basaria S, Coviello AD, Travison TG, et al. Adverse events with testosterone administration. N Engl J Med 2010, 363:109–122.CrossRefPubMedGoogle Scholar
  14. 14.
    Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005, 352:154–164.CrossRefPubMedGoogle Scholar
  15. 15.
    Cawthon PM, Ewing SK, McCulloch CE, et al. Loss of hip BMD in older men: the osteoporosis fractures in men (MrOS) study. J Bone Miner Res 2009, 24:1728–1735.CrossRefPubMedGoogle Scholar
  16. 16.
    Freitas SS, Barrett-Connor E, Ensrud KE, et al. Rate and circumstances of clinical vertebral fractures in older men. Osteoporos Int 2008, 19:615–623.CrossRefPubMedGoogle Scholar
  17. 17.
    Khosla S, Update in male osteoporosis. J Clin Endocrinol Metab 2010, 95:3–10.CrossRefPubMedGoogle Scholar
  18. 18.
    Lu-Yao GL, Albertsen PC, Moore DF, et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 2008, 300:173–181.CrossRefPubMedGoogle Scholar
  19. 19.
    Bruder JM, Ma JZ, Basler JW, Welch MD. Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy. Urology 2006, 67:152–155.CrossRefPubMedGoogle Scholar
  20. 20.
    • Chaganti RK, Parimi N, Lang T, et al. Bone mineral density and prevalent osteoarthritis of the hip in older men for the Osteoporosis fractures in men (MrOS) study group. Osteoporos Int 2010, 21:1307–1316. Although it has been known that arthritic changes in the spine affect bone density, this study shows that the hip BMD can be affected by arthritis as well. CrossRefPubMedGoogle Scholar
  21. 21.
    Greenspan SL. Approach to the prostate cancer patient with bone disease. J Clin Endocrinol Metab 2008, 93:2–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Nelson HD, Haney EM, Dana T, Bougatsos C, Chou R. Screening for osteoporosis: an update for the U.S. Preventive Services Task Force. Ann Intern Med 2010, published on line July 20.Google Scholar
  23. 23.
    Borgstrom F, Johnell O, Jonsson B, Zethraeus N, Sen SS. Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden. Bone 2004, 34:1064–1071.CrossRefPubMedGoogle Scholar
  24. 24.
    Schousboe JT, Taylor BC, Fink HA, et al. Cost effectiveness of bone densitometry followed by treatment of osteoporosis in older men. JAMA 2007, 298:629–637.CrossRefPubMedGoogle Scholar
  25. 25.
    Dawson-Hughes B, Toteston ANA, Melton LJ III, et al. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int 2008, 19:449–458.CrossRefPubMedGoogle Scholar
  26. 26.
    ISCD official positions 2007. www.iscd.org. Accessed October 25, 2010.
  27. 27.
    Qaseem A, Snow V, Shekelle P, et al. Screening for osteoporosis in men: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2008, 148:680–684.PubMedGoogle Scholar
  28. 28.
    Kanis JA, Johansson H, Oden A, et al. The effects of a FRAX® revision for the USA. Osteoporos Int 2010, 21:35–40.CrossRefPubMedGoogle Scholar
  29. 29.
    Binkley N, Adler RA: Dual-energy x-ray absorptiometry (DXA) in men. In Osteoporosis in Men, 2nd edition. Edited by Orwoll ES, Bilezikian JP, Vanderschueren D. New York, Academic Press; 2010:525–540.CrossRefGoogle Scholar
  30. 30.
    Cauley JA, Zmuda JM, Wisniewski SR, et al. Bone density and prevalent vertebral fractures in men and women. Osteoporos Int 2004, 15:32–37.CrossRefPubMedGoogle Scholar
  31. 31.
    • Sandhu SK, Nguyen ND, Center JR, et al. Prognosis of fracture: evaluation of predictive accuracy of the FRAX™ algorithm and the Garvan nomogram. Osteoporos Int 2009, published on line July 29. This is an interesting validation study in which the Garvan nomogram outperformed FRAX in men. Google Scholar
  32. 32.
    Hippisley-Cox J, Coupland C. Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. BMJ 2009, 339:b4229.CrossRefPubMedGoogle Scholar
  33. 33.
    • Donaldson MG, Cawthon PM, Lui LY, et al. Estimates of the proportion of older while men who would be recommended for pharmacologic treatment by the new US National Osteoporosis Foundation guidelines. J Bone Miner Res 2010, 25:1506–1511. This study demonstrates just how many men would be eligible for treatment based on the NOF guidelines. Google Scholar
  34. 34.
    Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid in reducing clinical fractures and mortality after hip fracture. N Engl J Med 2007, 357:1799–1809.CrossRefPubMedGoogle Scholar
  35. 35.
    Van der Klift, De Laet C, McCloskey EV, et al. Risk factors for incident vertebral fractures in men and women: the Rotterdam study. J Bone Miner Res 2004, 19:1172–1180.Google Scholar
  36. 36.
    Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000, 343:604–610.CrossRefPubMedGoogle Scholar
  37. 37.
    Ringe JD, Faber H, Farahmand P, Dorst A. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int 2006, 26:427–431.CrossRefPubMedGoogle Scholar
  38. 38.
    Johnson DA, Williams MI, Petkov VI, Adler RA, Zoledronic acid treatment of osteoporosis: effects in men. Endocr Pract 2010, published on line May 24.Google Scholar
  39. 39.
    Orwoll E, Miller P, Adachi J, et al. Efficacy and safety of once-yearly i.v. infusion of zoledronic acid 5 mg versus once-weekly 70 mg of oral alendronate in the treatment of male osteoporposis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res 2010, 25:2239–2250.CrossRefPubMedGoogle Scholar
  40. 40.
    Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1–34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003, 18:9–17.CrossRefPubMedGoogle Scholar
  41. 41.
    • Greenspan SL, Nelson JB, Trump DL, et al. Skeletal health after continuation, withdrawal, or delay of alendronate in men with prostate cancer undergoing androgen-deprivation therapy. J Clin Oncol 2008, 26:4426–4434. In men on ADT, stopping bisphosphonate therapy has consequences. CrossRefPubMedGoogle Scholar
  42. 42.
    Taxel P, Dowsett R, Richter L, et al. Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer. BJU Internat 2010, published on line April 30.Google Scholar
  43. 43.
    Bhoopalam N, Campbell SC, Moritz T, et al. Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy. J Urol 2009, 182:2257–2264.CrossRefPubMedGoogle Scholar
  44. 44.
    • Smith MR, Egerdie B, Toriz NH, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009, 361:745–755. Denosumab holds promise in men on ADT. CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC (outside the USA) 2010

Authors and Affiliations

  1. 1.Endocrinology and MetabolismMcGuire Veterans Affairs Medical CenterRichmondUSA

Personalised recommendations